Business Wire

Patient Safety Movement Foundation Honors Ruth Ann Dorrill, Kimberly Cripe, Dr. Peter Lachman with Humanitarian Awards and Dr. Mike Durkin with Lifetime Achievement Award

Share

Capping an eventful two days at the 11th Annual World Patient Safety, Science & Technology Summit, the Patient Safety Movement Foundation (PSMF) presented its prestigious Humanitarian Awards to visionaries and change agents in patient safety. The honorees were Ruth Ann Dorrill, Assistant Inspector General, Office of Evaluation and Inspections, Office of Inspector General; Kimberly Chavalas Cripe, the President and Chief Executive Officer at Children’s Hospital of Orange County; and Dr. Peter Lachman, Lead, Faculty Quality Improvement, Royal College of Physicians of Ireland. A special Lifetime Achievement Award was given to Dr. Mike Durkin, Chair of the PSMF’s Governance Board.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240909880433/en/

2024 Humanitarian Award recipients (left column, from top to bottom): Ruth Ann Dorrill, Assistant Inspector General, Office of Evaluation and Inspections, Office of Inspector General, with Joe Kiani and Dr. Mike Durkin; Kimberly Chavalas Cripe, the President and Chief Executive Officer at Children’s Hospital of Orange County, with Joe Kiani; Dr. Peter Lachman, Lead, Faculty Quality Improvement, Royal College of Physicians of Ireland, with Joe Kiani and Dr. Mike Durkin. Main image (right): Joe Kiani presents Dr. Mike Durkin with Lifetime Achievement Award. (Photo: Business Wire)

Each year since 2013, the PSMF’s Humanitarian Award is presented to a select group of distinguished individuals who have left an indelible mark on healthcare and helped shape the future of patient safety. As visionary leaders in their respective fields, they have implemented innovative, evidence-based, and sustainable solutions that transform the landscape of healthcare safety. This award honors their outstanding achievements so that they may serve as beacons of hope and sources of inspiration in the pursuit of zero harm and creating a safer, more just healthcare system for all.

The PSMF Lifetime Achievement Award is the highest award the PSMF can bestow. This individual will have made significant contributions in the area of patient safety throughout their career, and their achievements will have helped propel the medical community toward zero preventable patient and healthcare worker harm.

“It’s an honor to work with such a dedicated group of individuals whose contributions toward advancing patient safety are saving lives,” said PSMF Founder Joe Kiani. “As everyone in this field knows, we can’t do it alone, and these individuals represent the mentors we need to eliminate preventable patient harm in our hospitals and create a safer healthcare system for all.”

Ruth Ann Dorrill works for the U.S. Department of Health and Human Services as the Assistant Inspector General in the Office of Evaluation and Inspections, Office of Inspector General (OIG). Dorrill has been with the OIG for 28 years, leading the OIG’s work in patient harm for 15 years. She has led national studies in evaluating hospital and nursing quality, safety, and emergency preparedness, and has directed management reviews of HHS programs, including the Centers for Medicare & Medicaid Services implementation of HealthCare.gov and management of the Indian Health Service. She has testified before the U.S. House of Representatives Energy and Commerce Committee regarding nursing home quality and in 2021 received the Council of the Inspectors General on Integrity and Efficiency Lifetime Achievement Award.

As the President and Chief Executive Officer of Children’s Hospital of Orange County (CHOC) since 1997, Kimberly Chavalas Cripe has made significant advances in improving patient care, outcomes, and experience, while cultivating a growing healthcare community rooted in a culture of safety, excellence, innovation, and collaboration. Under Cripe’s leadership, CHOC has become a forerunner of population health management with the singular goal of fulfilling CHOC’s mission to advance and protect the health and well-being of children. Among many other initiatives, Cripe spearheaded efforts at CHOC to establish a robust pediatric system of mental healthcare designed to be scalable and replicable by other health systems. Cripe also serves as president of the CHOC Foundation, which raises funds to support pediatric healthcare.

Dr. Peter Lachman serves as Lead, Faculty Quality Improvement, at the Royal College of Physicians of Ireland (RCPI) in Dublin, where he directs the Leadership and Quality program to develop clinical leaders in quality improvement. He was Chief Executive Officer of the International Society for Quality in Healthcare (ISQua) from 2016 to 2021 and was a Health Foundation Quality Improvement Fellow at the Institute for Healthcare Improvement in 2005–2006. Dr. Lachman was also the National Clinical Lead for SAFE, a Royal College of Paediatrics and Child Health program that aims to improve situation awareness in clinical teams across England and Ireland. In addition, his work for PSMF includes editing Handbook publications on patient safety, medical management, and quality improvement, and leading the Global Interprofessional Patient Safety Fellowship program.

Dr. Mike Durkin, who is the current Chair of the Patient Safety Movement Foundation’s Governance Board, was honored with a special Lifetime Achievement Award by PSMF Founder Joe Kiani. In addition to his work for PSMF, Dr. Durkin is the Senior Advisor on Patient Safety Policy and Leadership, Institute of Global Health Innovation, Imperial College London. He is recognized as one of the world’s foremost authorities on patient safety and holds numerous advisory positions, serving as Senior Advisor on Patient Safety Policy and Leadership for the NIHR Imperial College Patient Safety Translational Research Centre in the U.K., and Academic Director of the Global Patient Safety Collaborative, a partnership between the World Health Organization (WHO) and the U.K. government. Dr. Durkin previously held clinical, research, and teaching positions in cardiovascular anesthesia and critical care in the U.K. and the U.S. before embarking on a 25-year career in medical management and leadership, culminating in an appointment as National Health Service (NHS) Medical Director across the South of England. Durkin subsequently served as the NHS National Director of Patient Safety.

PATIENT SAFETY MOVEMENT FOUNDATION

In 2012, Joe Kiani founded the nonprofit Patient Safety Movement Foundation to eliminate preventable medical errors in hospitals. His team worked with patient safety experts from around the world to create Actionable Evidence-Based Practices that address top challenges. Hospitals can make a formal commitment to ZERO preventable deaths, and healthcare technology companies are asked to sign the Open Data Pledge to share their data so that predictive algorithms can be developed to identify errors before they become fatal. The PSMF was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240909880433/en/

Contacts

Patient Safety Movement Foundation

Patient Safety Movement Foundation
Irene Mulonni, irene@mulonni.com | (858) 859-7001

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye